Send to

Choose Destination
Cell Reprogram. 2017 Aug;19(4):217-224. doi: 10.1089/cell.2016.0062. Epub 2017 May 18.

Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Past, Present, and Future.

Author information

1 Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens , Athens, Greece .
2 Cell and Gene Therapy Laboratory, Centre of Basic Research II , Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece .


The concept of Regenerative Medicine combined with Cell based Therapy and Tissue Engineering represents the fourth pillar of healthcare and provides a promising approach for the treatment of serious diseases. Recently, cell based therapies are focused on the use of mesenchymal stem/stromal cells (MSCs). Human MSCs, that represent a mesoderm derived population of progenitors, are easily expanded in culture. They are capable to differentiate into osteoblasts, chondrocytes, and adipocytes and exhibit the potential to repair or regenerate damaged tissues. The best characterized source of human MSCs to date is the bone marrow; recently, fetal sources, such as amniotic fluid, umbilical cord, amniotic membranes, or placenta, have also attracted increased attention. Thus, MSCs may represent a valuable tool for tissue repair and cell therapeutic applications. To this end, the main focus of this review is to summarize and evaluate the key characteristics, the sources, and the potential use of MSCs in therapeutic approaches and modalities.


Regenerative Medicine; fetal cells; mesenchymal stem/stromal cells; paracrine action; secretome

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center